Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury
Authors:
- Marco FaillaMFMarco Failla
- Tiziana GenoveseTGTiziana Genovese
- Emanuela MazzonEMEmanuela Mazzon
- Elisa GiliEGElisa Gili
- Carmelo MuiàCMCarmelo Muià
- Mariangela SortinoMSMariangela Sortino
- Nunzio CrimiNCNunzio Crimi
- Achille P CaputiACAchille P Caputi
- Salvatore CuzzocreaSalvatore Cuzzocrea
- Carlo VancheriCVCarlo Vancheri
Open Access
- 21 November 2006
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 7 (1) , 1-12
Abstract
Leukotrienes are increased locally in idiopathic pulmonary fibrosis. Furthermore, a role for these arachidonic acid metabolites has been thoroughly characterized in the animal bleomycin model of lung fibrosis by using different gene knock-out settings. We investigated the efficacy of pharmacological inhibition of leukotrienes activity in the development of bleomycin-induced lung injury by comparing the responses in wild-type mice with mice treated with zileuton, a 5-lipoxygenase inhibitor and MK-571, a cys-leukotrienes receptor antagonist. Mice were subjected to intra-tracheal administration of bleomycin or saline and were assigned to receive either MK-571 at 1 mg/Kg or zileuton at 50 mg/Kg daily. One week after bleomycin administration, BAL cell counts, lung histology with van Gieson for collagen staining and immunohistochemical analysis for myeloperoxidase, IL-1 and TNF-α were performed. Following bleomycin administration both MK-571 and zileuton treated mice exhibited a reduced degree of lung damage and inflammation when compared to WT mice as shown by the reduction of:(i) loss of body weight, (ii) mortality rate, (iii) lung infiltration by neutrophils (myeloperoxidase activity, BAL total and differential cell counts), (iv) lung edema, (v) histological evidence of lung injury and collagen deposition, (vi) lung myeloperoxidase, IL-1 and TNF-α staining. This is the first study showing that the pharmacological inhibition of leukotrienes activity attenuates bleomycin-induced lung injury in mice. Given our results as well as those coming from genetic studies, it might be considered meaningful to trial this drug class in the treatment of pulmonary fibrosis, a disease that still represents a major challenge to medical treatment.Keywords
This publication has 43 references indexed in Scilit:
- 5-LIPOXYGENASE MODULATES THE ALTERATION OF PARACELLULAR BARRIER FUNCTION IN MICE ILEUM DURING EXPERIMENTAL COLITISShock, 2006
- Effect of montelukast on nuclear factor κB activation and proinflammatory moleculesAnnals of Allergy, Asthma & Immunology, 2005
- Involvement of LTD4in allergic pulmonary inflammation in mice: modulation by cysLT1antagonist MK-571Prostaglandins, Leukotrienes and Essential Fatty Acids, 2000
- REGULATION OF 5-LIPOXYGENASE METABOLISM IN MONONUCLEAR PHAGOCYTES BY CD4 T LYMPHOCYTESExperimental Lung Research, 1999
- Co‐expression of TNFα and IL‐1β in human acute pulmonary fibrotic diseases: An immunohistochemical analysisPathology International, 1996
- Effects of 5−Lipoxygenase Inhibitors on Interleukin Production by Human Synovial Tissues in Organ Culture: Comparison with Interleukin−1−synthesis InhibitorsJournal of Pharmacy and Pharmacology, 1996
- The Leukotriene LTD4 Receptor Antagonist Mk571 Specifically Modulates MRP Associated Multidrug ResistanceBiochemical and Biophysical Research Communications, 1995
- Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in miceEuropean Respiratory Journal, 1994
- ATP‐dependent leukotriene export from mastocytoma cellsFEBS Letters, 1991
- Binding of leukotriene C4 to rat lung fibroblasts and stimulation of collagen synthesis in vitroBiochemistry, 1988